This present disclosure is directed to a method of treating a subject with cancer with a combination of a protein kinase C (PKC) activator and a second therapeutic agent.
本公开涉及一种用蛋白激酶 C (PKC) 激活剂和第二种治疗剂组合治疗癌症患者的方法。
Syntheses, biological evaluation and SAR of ingenol mebutate analogues for treatment of actinic keratosis and non-melanoma skin cancer
Ingenol mebutate is the active ingredient in Picato (R) a new drug for the treatment of actinic keratosis. A number of derivatives related to ingenol mebutate were prepared by chemical synthesis from ingenol with the purpose of investigating the SAR and potency in assays relating to pro-inflammatory effects (induction of PMN oxidative burst and keratinocyte cytokine release), the potential of cell death induction, as well as the chemical stability. By modifications of the ingenol scaffold several prerequisites for activity were identified. The chemical stability of the compounds could be linked to an acyl migration mechanism. We were able to find analogues of ingenol mebutate with comparable in vitro properties. Some key features for potent and more stable ingenol derivatives have been identified. (C) 2013 Elsevier Ltd. All rights reserved.
This present disclosure is directed to a method of treating a subject with cancer with a combination of a protein kinase C (PKC) activator and a second therapeutic agent.
[EN] METHODS OF CANCER TREATMENT<br/>[FR] MÉTHODES DE TRAITEMENT DU CANCER
申请人:K-GEN INC
公开号:WO2017083783A2
公开(公告)日:2017-05-18
This present disclosure is directed to a method of selecting a cancer for treatment with protein kinase C (PKC) activators, and corresponding methods of treating the cancer with PKC activators.